EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Riluzole‐Derived Benzo[d]thiazoles as CK1 δ Inhibitors for Amyotrophic Lateral Sclerosis‐Related Neurodegeneration

Simone Adorinni iD, Ilenia Grieco iD, Stefano Morasso, Michelle Fornasier iD, Gianluca Novello iD, Veronica Salmaso, Loreto Martínez-González, Eleonora Cescon, Davide Bassani, Giovanni Adriano Bassan iD, Teresa Gianferrara, Filippo Prencipe and 7 more

ChemMedChem · 2026-10-28 · 21 (20)

DOI: 10.1002/cmdc.70539 ↗

At a glance

Journal article in ChemMedChem, published online on 2026-10-22. Written by Simone Adorinni and 18 co-authors. Institution: Department of Chemical and Pharmaceutical Sciences, University of Trieste, Trieste, Italy. Major MEDLINE topics: Amyotrophic Lateral Sclerosis, Riluzole, Casein Kinase Idelta, Protein Kinase Inhibitors. 66 references. The full text is freely available (open access, CC BY 4.0). Funded by: Ministero dell'Istruzione, dell'Università e della Ricerca, Ministero dell’Istruzione, dell’Università e della Ricerca.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Riluzole‐derived benzo[d]thiazoles were investigated as metabolite‐inspired CK1 δ inhibitors, a kinase involved in TDP‐43 phosphorylation and therefore relevant to amyotrophic lateral sclerosis (ALS). Starting from the known CK1 δ activity of riluzole, we examined whether its major hydroxylamine metabolite could preserve target recognition and provide a rational entry point for scaffold optimisation. The metabolite retained CK1 δ inhibition, but its limited chemical stability and toxicity in neuronal cells identified the hydroxylamine group as a critical liability. Replacement of this functionality with a hydrazine converted the fragile metabolite‐derived structure into a more potent and tractable CK1 δ inhibitor series. Structure–activity relationship studies revealed that the hydrazine moiety accommodates broader substitution than the hydroxylamine counterparts, with branched alkyl and benzyl groups giving the most balanced profiles. Docking and molecular dynamics suggested that the improvement could be attributed to an additional hydrogen‐bond with Gly86 in the hinge region. The best derivative combined submicromolar CK1 δ inhibition with passive blood–brain barrier permeability, short‐term cellular tolerance, ATP competitive inhibition, direct target engagement, and preliminary selectivity over GSK3β. Although this compound did not result neuroprotective in an oxidative stress model, it paves the way for a focused benzo[d]thiazole platform for probing CK1 δ biology in ALS.

Subjects

MeSH terms (MEDLINE)

Amyotrophic Lateral SclerosisRiluzoleCasein Kinase IdeltaProtein Kinase InhibitorsBenzothiazolesNeuroprotective AgentsHumansStructure-Activity RelationshipAnimalsMolecular Docking SimulationMolecular Structure

Author keywords

Casein kinase 1δbenzo[d]thiazoleslateral sclerosismetabolism‐based drug designriluzole

Substances

RiluzoleCasein Kinase IdeltaProtein Kinase InhibitorsBenzothiazolesNeuroprotective Agents

Authors and institutions

  • Department of Chemical and Pharmaceutical Sciences, University of Trieste, Trieste, Italy.
  • Protein Targets for Drug Discovery Lab, Structural Biology, Elettra Sincrotrone Trieste S.C.p.A, Basovizza, Italy.
  • Molecular Modelling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padova, Italy.
  • Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.

ORCID profiles: Simone Adorinni, Ilenia Grieco, Michelle Fornasier, Gianluca Novello, Giovanni Adriano Bassan, Tatiana Da Ros, Paola Storici, Ana Martinez, Giampiero Spalluto, Stefano Moro, Stephanie Federico

Funding

  • Ministero dell'Istruzione, dell'Università e della Ricerca
  • Ministero dell’Istruzione, dell’Università e della Ricerca

Cite

APA

Adorinni, S., Grieco, I., Morasso, S., Fornasier, M., Novello, G., Salmaso, V., Martínez-González, L., Cescon, E., Bassani, D., Bassan, G. A., Gianferrara, T., Prencipe, F., Kost, V., Da Ros, T., Storici, P., Martinez, A., Spalluto, G., Moro, S., & Federico, S. (2026). Riluzole‐Derived Benzo[d]thiazoles as CK1 δ Inhibitors for Amyotrophic Lateral Sclerosis‐Related Neurodegeneration. ChemMedChem, 21(20). https://doi.org/10.1002/cmdc.70539

Vancouver

Adorinni S, Grieco I, Morasso S, Fornasier M, Novello G, Salmaso V, et al. Riluzole‐Derived Benzo[d]thiazoles as CK1 δ Inhibitors for Amyotrophic Lateral Sclerosis‐Related Neurodegeneration. ChemMedChem. 2026;21(20). doi:10.1002/cmdc.70539

BibTeX
@article{Adorinni2026,
  author = {Adorinni, Simone and Grieco, Ilenia and Morasso, Stefano and Fornasier, Michelle and Novello, Gianluca and Salmaso, Veronica and Martínez-González, Loreto and Cescon, Eleonora and Bassani, Davide and Bassan, Giovanni Adriano and Gianferrara, Teresa and Prencipe, Filippo and Kost, Veronika and Da Ros, Tatiana and Storici, Paola and Martinez, Ana and Spalluto, Giampiero and Moro, Stefano and Federico, Stephanie},
  title = {Riluzole‐Derived Benzo[d]thiazoles as CK1 δ Inhibitors for Amyotrophic Lateral Sclerosis‐Related Neurodegeneration},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {20},
  doi = {10.1002/cmdc.70539}
}
Start for free →